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OBJECTIVES We examined the association of hormone therapy (HRT) with hemorrhagic and ischemic
stroke among postmenopausal women with acute myocardial infarction (AMI).
BACKGROUND Hemorrhagic and ischemic strokes are common complications of AMI, and women are at
increased risk for hemorrhagic stroke after thrombolytic therapy. This risk may be related to
female hormones.
METHODS Using data from the National Registry of Myocardial Infarction-3, we studied 114,724
women age 55 years or older admitted to the hospital for AMI, of whom 7,353 reported HRT
use on admission. We determined rates of in-hospital hemorrhagic and ischemic stroke
stratified by HRT use and estimated the independent association of HRT with each stroke
type using multivariable logistic regression.
RESULTS The HRT users were younger than non-users, had fewer risk factors for stroke including
diabetes and prior stroke, and received more pharmacologic and invasive therapy including
cardiac catheterization. A total of 2,152 (1.9%) in-hospital strokes occurred, with 442 (0.4%)
hemorrhagic, 1,017 (0.9%) ischemic and 693 (0.6%) unspecified. Among HRT users and
non-users, the rates of hemorrhagic stroke (0.40% vs. 0.42%, p  1.00) and ischemic stroke
(0.80% vs. 0.96%, p  0.11) were similar. Among 13,328 women who received thrombolytic
therapy, the rate of hemorrhagic stroke was not significantly different for users and non-users
(1.6% vs. 2.1%, p 0.22). After adjustment for baseline and treatment differences, HRT was
not associated with hemorrhagic (odds ratio [OR], 0.88; 95% confidence intervals [CI], 0.58
to 1.35) or ischemic stroke (OR, 0.89; CI, 0.66 to 1.18).
CONCLUSIONS Acute myocardial infarction is a high-risk setting for stroke among postmenopausal women,
but HRT does not appear to modify that risk. Clinicians should not alter their approach to
thrombolytic therapy based on HRT use. (J Am Coll Cardiol 2001;38:1297–301) © 2001 by
the American College of Cardiology
Controversy surrounds the use of hormone therapy (HRT)
to reduce cardiovascular events in postmenopausal women.
Observational studies have found a beneficial effect on
coronary heart disease events (1,2), but the first randomized
trial to study the effect of HRT on coronary disease
outcomes, the Heart and Estrogen/progestin Replacement
Study (HERS), found no effect of HRT for secondary
prevention of cardiac events (3). The association of HRT
with stroke risk is also controversial. Although the use of
estrogens for contraception has been associated with in-
creased risk of ischemic and hemorrhagic stroke (4,5),
longitudinal studies of HRT in postmenopausal women
have been conflicting, with findings of increased (2,6),
decreased (7) and no risk (8) for ischemic stroke. The few
observational studies of hemorrhagic stroke have observed
HRT to be associated with decreased risk (9,10). In the
HERS trial, however, HRT had no effect on risk for the 215
cerebrovascular events that occurred (11). No study has
examined the impact of HRT on stroke risk after acute
myocardial infarction (AMI).
The risk of stroke is high after AMI, with an incidence of
up to 2% at 30 days in unselected patients (12,13). The risk
is highest in patients receiving thrombolytic therapy, due to
an increased risk of intracranial hemorrhage, but ischemic
strokes are also common (13,14). Risk factors for ischemic
stroke after AMI include older age, diabetes, prior stroke or
transient ischemic attack, previous angina and history of
hypertension (15). Independent risk factors for hemorrhagic
stroke after thrombolysis are older age, black race, prior
stroke, elevated blood pressure (BP), lower body weight and,
interestingly, female gender (16), raising the possibility that
female hormones might have some impact on cerebrovas-
cular disease or response to therapy. To address this possi-
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bility, we evaluated the association of HRT use at the time
of hospital admission for AMI with hemorrhagic and
ischemic stroke.
METHODS
The third National Registry of Myocardial Infarction
(NRMI-3) is a nationwide, prospective cohort study spon-
sored by Genentech, Inc. (South San Francisco, California),
in which data are collected regarding clinical characteristics,
treatment patterns and outcomes of patients presenting with
AMI. The 1,674 participating hospitals are encouraged to
enroll consecutive patients with AMI, regardless of treat-
ments used or outcomes observed. Data are collected on
prespecified forms by a study coordinator at each hospital
and forwarded to a central agency for compilation (STAT-
Probe, Inc., Lexington, Kentucky). Double key data entry
and electronic data checks are routinely performed to ensure
accuracy, consistency and completeness, which have com-
pared favorably with the independently validated Coopera-
tive Cardiovascular Project (17). Confirmation of AMI
requires an International Classification of Diseases version 9
hospital discharge diagnosis code of 410.x1 and a patient
history and clinical presentation suggestive of AMI com-
bined with any of the following: a total creatine kinase (or
MB fraction) at least twice the hospital’s upper limit of
normal; electrocardiographic evidence of AMI; or alterna-
tive enzymatic, scintigraphic, echocardiographic or autopsy
evidence indicative of AMI.
Study subjects. From April 1, 1998 to January 31, 2000,
404,106 men and women with AMI were enrolled in
NRMI-3. Patients who were transferred to another hospital
were excluded because of missing information on their vital
status at hospital discharge (n  86,205). Because NRMI-3
does not collect information on menopausal status, we limited
our analysis to women age 55 years or older, which resulted in
a cohort of 114,724 women with documented AMI.
Measurements. The primary predictor of interest was use
of HRT prior to hospital admission. Hormone therapy was
defined as “the current use of estrogen, progestin, or
estrogen/progestin for reasons other than contraception.”
Women were coded as current users or non-users of HRT,
but information on past use, dose, preparation, cyclic or
non-cyclic administration, or duration of use was not
available. Data were also collected on demographic charac-
teristics (age, race and region of residence in the US), past
medical history (diabetes, hypertension, prior stroke, prior
AMI, congestive heart failure [CHF], percutaneous trans-
luminal coronary angioplasty [PTCA], coronary artery by-
pass graft surgery [CABG], hypercholesterolemia and fam-
ily history of coronary artery disease), presentation
characteristics (presence of chest pain, systolic and diastolic
BPs, heart rate, Killip class at initial evaluation, electrocar-
diogram findings and location of infarct) and treatments
during the index hospitalization (medications and proce-
dures).
The primary outcome was stroke occurring during the
AMI hospitalization. The diagnosis of stroke required
documentation of any new neurologic deficit by a treating
physician. Radiographic imaging was not required for stroke
diagnosis. For this analysis, strokes were divided into two
classifications. Ischemic stroke was defined as “thromboem-
bolic” or “thromboembolic with hemorrhagic conversion,”
and hemorrhagic strokes were only primary “hemorrhagic”
stroke types. Hemorrhagic strokes were verified with com-
puted tomography or magnetic resonance imaging in 92.5%
of reported cases.
Statistical analysis. Admission characteristics, in-hospital
treatment, and outcomes of users and non-users of HRT were
compared using the t test for continuous variables and the
chi-square test for categorical variables. Because of the large
sample size in NRMI-3, differences with little clinical rele-
vance may achieve statistical significance. Multivariable logistic
regression was used to adjust for differences in baseline char-
acteristics and treatments received in-hospital. A backward
stepwise elimination procedure was used to select variables to
remain in the final model with a significance threshold of p
0.05. We conducted subgroup analyses based on decade of age
and use of thrombolytic therapy by constructing multivariable
models within these a priori subgroups. The presence of a
statistical interaction of HRT use with age and thrombolytic
use was assessed via an interaction term in the multivariable
models for each stroke type.
In addition, propensity score methods were employed to
adjust for residual selection bias (18). First, a multivariable
logistic regression model was constructed with HRT use
(yes/no) as the outcome variable and admission character-
istics as the predictor variables. The coefficients from this
analysis were used to calculate the likelihood of receiving
HRT for each patient in the sample, whether they actually
received HRT or not, and these likelihoods were grouped
into deciles. These “propensity to receive HRT” deciles were
then entered as predictor variables in the multivariable
models, with each stroke subtype as the outcome. Thus, we
attempted to adjust the association of HRT with stroke risk
for differences in the propensity to receive HRT in order to
reduce the influence of confounding. The predictive value of
each model was assessed using the c statistic. The SAS
Abbreviations and Acronyms
AMI  acute myocardial infarction
BP  blood pressure
CABG  coronary artery bypass graft surgery
CHF  congestive heart failure
CI  confidence intervals
HERS  Heart and Estrogen/progestin Replacement
Study
HRT  hormone therapy
NRMI-3  National Registry of Myocardial Infarction
OR  odds ratio
PTCA  percutaneous transluminal coronary
angioplasty
WEST  Women’s Estrogen for Stroke Trial
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statistical package was used for all statistical analyses (SAS
8.0, SAS Institute Inc., Cary, North Carolina).
RESULTS
Among the 114,724 women with AMI in NRMI-3 aged 55
years or older, 7,353 (6.4%) were current users of HRT at
the time of hospital admission. The HRT users were
younger, more likely to be white and to smoke, and more
likely to have hypercholesterolemia or a family history of
premature coronary artery disease, but less likely to have a
history of diabetes, heart failure, prior MI or prior stroke
than non-users (Table 1). At initial presentation, HRT
users had slightly higher systolic BP and lower heart rates,
were more likely to complain of chest pain and had fewer
signs of heart failure (Killip Class II–IV).
After hospital admission, HRT users received more
pharmacologic and invasive therapy than non-users. They
were more likely to receive aspirin (87% vs. 79%), heparin
(74% vs. 64%), and thrombolytic agents (19% vs. 12%, all
p  0.001). The HRT users were also more likely to
undergo invasive cardiac procedures during hospitalization,
including coronary angiography (65% vs. 42%), primary
PTCA (9% vs. 6%) or any percutaneous coronary interven-
tion (25% vs. 15%) and CABG (12% vs. 8%, all p 0.001).
Hormone use and stroke. During the index hospitaliza-
tion, stroke occurred in 2,152 women (1.9%, 95% confi-
dence intervals [CI], 1.8% to 2.0%), including 442 (0.4%)
hemorrhagic, 1,017 (0.9%) ischemic and 693 (0.6%) un-
specified strokes. Although the overall stroke incidence was
marginally lower for HRT users, we observed no statistically
significant differences in the crude incidence of either
hemorrhagic or ischemic stroke (Table 2). Among women
receiving thrombolytic therapy, similar rates of hemorrhagic
stroke were observed for users and non-users of HRT (1.6%
vs. 2.1%, p  0.22). In-hospital mortality was high among
women suffering a stroke but was not different between
HRT users and non-users (42% vs. 40%, p  0.61).
In a multivariable model adjusting for differences between
HRT users and non-users, HRT use was not significantly
associated with the incidence of hemorrhagic stroke among
all women (odds ratio [OR], 0.88; 95% CI, 0.58 to 1.35) or
among those women receiving thrombolytic therapy (OR,
1.05; 95% CI, 0.65 to 1.69). Variables retained in the final
Table 1. Characteristics of Postmenopausal Women With Acute
Myocardial Infarction According to Use of Hormone Therapy
on Admission*
Hormone
Therapy
Users
(n  7,353)
Hormone
Therapy
Non-Users
(n  107,371)
Mean age, yr 71 77
Age group, yr, %
55–64 32 14
65–74 36 27
75–84 26 36
84 7 23
Ethnicity, %
White 91 85
Black 4 8
Other 5 7
Diabetes mellitus, % 25 35
Hypertension,† % 65 66
Hypercholesterolemia, % 40 26
Current smoker, % 21 14
Angina,‡ % 14 15
Heart failure, % 14 25
Prior event, %
Myocardial infarction 19 24
Stroke 9 14
Coronary angioplasty 10 8
Coronary artery bypass§ 10 10
Family history of coronary disease, % 30 20
First systolic blood pressure, mm Hg 146 144
First diastolic blood pressure, mm Hg 79 78
First heart rate, beats/min 86 90
Chest pain present, % 71 56
Killip class, %
I 79 64
II 14 23
III 6 12
IV 1 2
ST segment elevation or left
bundle-branch block, %
39 36
Anterior myocardial infarction, % 26 24
Admission diagnosis of
myocardial infarction, %
41 36
*Except as indicated, all p  0.01; †p  0.07; ‡p  0.34; §p  0.94.
Table 2. In-Hospital Ischemic and Hemorrhagic Stroke Among
Postmenopausal Women With Acute Myocardial Infarction
According to Use of Hormone Therapy on Admission
HRT Users
HRT
Non-Users
p
Value
All postmenopausal women n  7,353 n  107,371
Ischemic strokes,* n (%) 56 (0.80) 961 (0.96) 0.11
Unadjusted odds ratio
(95% CI)
0.84 (0.64–1.10) — 0.19
Adjusted odds ratio†
(95% CI)
0.89 (0.66–1.18) — 0.41
Hemorrhagic strokes, n (%) 28 (0.40) 414 (0.42) 1.00
Unadjusted odds ratio
(95% CI)
0.97 (0.66–1.42) — 0.88
Adjusted odds ratio‡
(95% CI)
0.88 (0.58–1.35) — 0.57
Postmenopausal women
receiving thrombolysis
n  1,286 n  12,042
Hemorrhagic strokes, n (%) 20 (1.6) 256 (2.1) 0.22
Unadjusted odds ratio
(95% CI)
0.73 (0.46–1.15) — 0.17
Adjusted odds ratio‡
(95% CI)
1.05 (0.65–1.69) — 0.85
*Defined as thromboembolic or thromboembolic with hemorrhagic conversion; †The
following variables were retained in the final model for ischemic stroke: history of
hypertension, congestive heart failure, stroke, or coronary artery bypass graft; chest
pain on admission; systolic blood pressure on admission; anterior acute myocardial
infarction (AMI); ST segment elevation or depression; admission diagnosis of
“unstable angina”; any cardiac catheterization; and any use of percutaneous translu-
minal coronary angioplasty (PTCA); and ‡the following variables were retained in the
final model for hemorrhagic stroke: history of diabetes, AMI, stroke, or PTCA; chest
pain on admission, systolic BP on admission; Killip Class I; ST segment elevation;
admission diagnosis “other”; any cardiac catheterization; use of thrombolytic therapy;
and use of primary PTCA.
CI  confidence intervals.
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model were history of diabetes, AMI, stroke or PTCA;
chest pain on admission; systolic BP on admission; Killip
Class  I; ST segment elevation; admission diagnosis
“other”; any cardiac catheterization; use of thrombolytic
therapy; and use of primary PTCA. The c statistic for the
hemorrhagic model was 0.82 among all patients and 0.78
among patients treated with thrombolysis. Similarly, after
adjustment, HRT use was not significantly associated with
the incidence of ischemic stroke (OR, 0.89; 95% CI, 0.66 to
1.18). Variables retained in the final model were history of
hypertension, CHF, stroke or CABG; chest pain on admis-
sion; systolic BP on admission; anterior AMI; ST segment
elevation or depression; admission diagnosis of “unstable
angina”; any cardiac catheterization; and any use of PTCA.
The c statistic for the ischemic model was 0.65. There was
no significant interaction between age and HRT use for
ischemic stroke (p 0.07) or for hemorrhagic stroke, either
among all postmenopausal women (p  0.70) or among
those women receiving thrombolysis (p  0.12).
DISCUSSION
In this large, community-based cohort, we found that stroke
complicates 1 of every 50 AMI admissions among post-
menopausal women and is associated with a 40% in-hospital
mortality rate. There were no significant differences be-
tween current HRT users and non-users in the incidence of
either hemorrhagic or ischemic stroke or in overall stroke
mortality. Hormone therapy use did not appear to modify
the risk of hemorrhagic stroke associated with thrombolytic
therapy.
Prior studies of HRT and stroke. Previous observational
studies of HRT in postmenopausal women have found con-
flicting results regarding its association with risk for stroke.
Estimates of the association of HRT and ischemic stroke range
from a 30% decreased risk (7) to a threefold increased risk (6),
with other studies showing no association (8). A limitation of
several studies is that ischemic and hemorrhagic strokes were
not distinguished, despite their differences in pathophysiology.
Two case-control studies found HRT to be associated with a
40% to 60% decreased risk for hemorrhagic stroke, but these
studies based their findings on fewer than 100 cases with
known HRT status (9,10).
Recent randomized trials of HRT for secondary preven-
tion of cardiovascular disease have examined its effect on
stroke risk. In the HERS trial, over 2,700 women with a
known history of coronary artery disease were randomly
assigned to receive either conjugated estrogen (0.625 mg/d)
and medroxyprogesterone acetate (2.5 mg/d) or placebo and
followed for a mean period of 4.1 years. The HRT users,
compared with non-users, had a 2% higher absolute inci-
dence of prespecified ischemic or hemorrhagic stroke or
transient ischemic attack, but this difference was not statis-
tically significant (7% vs. 5%, p  0.20). No significant
difference in hemorrhagic (n  13) or ischemic (n  128)
strokes was observed (11). In the Women’s Estrogen for
Stroke Trial (WEST), 652 postmenopausal women who
had experienced a non-disabling stroke or transient isch-
emic attack were randomized to treatment with 17-beta
estradiol (1 mg/d) or placebo with an average follow-up of
2.7 years. The primary endpoint of all-cause death or
nonfatal stroke occurred in 27.6% of estradiol-treated pa-
tients and 27.7% of placebo-treated patients (p  0.80),
with stroke occurring in 16.8% and 17.4% (p  0.83),
respectively (19). Estradiol was associated with a more than
two-fold increase in the risk of stroke at 6 months; death
due to stroke had occurred in 12 women assigned to
estradiol therapy but only three women assigned to placebo
therapy. (Data presented by Lawrence M. Brass at the 26th
International Stroke Conference of the American Stroke
Association, February 2001.) These trials suggest that HRT
does not protect against ischemic or hemorrhagic stroke and
may be associated with an early increase in risk.
The present study has several unique strengths. First, to
our knowledge, this is the largest cohort of postmenopausal
women with AMI studied to date, with detailed data
collected on over 114,000 women, over 7,000 of whom were
HRT users. Second, although the period of observation in
NRMI-3 is relatively short, extending only through the
duration of the AMI hospitalization, the number of stroke
events (2,152) exceeds that of any prior study, providing
adequate power to observe clinically relevant associations
between HRT and stroke after AMI. Detailed information
was collected on the type of stroke in our cohort, and our
ability to distinguish hemorrhagic and ischemic events
extends the findings of previous observational studies. Fi-
nally, this is the first study to examine the association of
HRT with stroke in the setting of AMI.
AMI: a high-risk period for stroke. Stroke is a relatively
common occurrence in AMI whether thrombolytic therapy,
primary angioplasty, or no reperfusion therapy is used. In the
Global Use of Strategies to Open Occluded Coronary Arteries
trial, ischemic stroke occurred in 1.4% of patients receiving
thrombolytic therapy (12). The rate of stroke may be even
higher in community settings. In NRMI-2, stroke occurred in
2.0% of patients receiving tissue plasminogen activator, more
often in women than in men (3.3% vs. 1.4%, p  0.001), but
stroke also occurred in 0.9% of patients receiving no reperfu-
sion therapy (14). Female gender was found to be an indepen-
dent risk factor for hemorrhagic stroke after thrombolysis,
increasing the risk by almost 60% compared with men (16).
Various mechanisms have been proposed by which female
hormones might increase or decrease stroke risk. Hormone
therapy increases risk for venous thromboembolic events
about threefold (20). If the mechanisms of this increased
risk is hypercoagulability, risk for embolic stroke might also
be increased. In the Stroke Prevention in Atrial Fibrillation
trials, women with atrial fibrillation, in whom emboli are
the most likely cause of stroke, had a greater risk of stroke
if they were HRT users (6). After an AMI, hypokinesis of
the ventricular wall promotes thrombus formation and
subsequent embolism, and any hypercoagulable effects of
HRT in this setting might be expected to increase stroke
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risk. As a potential mechanism for hemorrhagic stroke risk,
estrogen appears to modulate the endogenous fibrinolytic
potential in women (21), and bleeding rates are higher in
women than in men receiving thrombolytic therapy (22).
However, in the present study, the lack of association
between HRT and hemorrhagic stroke argues against any
significant clinical impact of HRT that would explain these
observed differences between men and women. That there
was no increase in risk for hemorrhagic stroke among
women taking HRT who received thrombolytic therapy
should reassure clinicians who treat women with AMI.
Study limitations. Our study design is observational, and
like all such studies, the results may be biased if the two
groups of women are different in ways other than HRT use.
Although we adjusted for certain characteristics associated
with better health in women taking HRT using extensive
multivariable models, residual confounding due to selection
and adherence biases may still be present. We did use
propensity score methods in an attempt to address this
residual confounding. Outcomes were observed only until
hospital discharge, and any strokes occurring after hospital
discharge were not included in the analysis. Because over
75% of hemorrhagic strokes occur within 24 h of thrombo-
lytic therapy (12), these two biases should have less impact
on the observed association with hemorrhagic stroke.
No information was available on in-hospital use of HRT,
so the short-term effects of HRT on stroke incidence or
severity could not be assessed. Finally, HRT may be
associated with early harm as seen in the HERS trial (3) and
the WEST trial reviewed above, but information on the
duration and formulation of HRT was not recorded in
NRMI, so no comparisons between recent and long-term
HRT use could be made.
CONCLUSIONS
Stroke is common among postmenopausal women hospi-
talized for AMI, occurring in about 1 in 50 patients. Among
more than 114,000 such women, we found no evidence that
use of HRT alters risk for ischemic or hemorrhagic stroke or
stroke case fatality. Among over 13,000 women who re-
ceived thrombolysis, there was no increased risk for hem-
orrhagic stroke among HRT users compared to non-users.
Clinicians should not alter their approach to thrombolytic
therapy in AMI based on HRT use.
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